Jamjoom Pharma Stock (4015): Price, GoFinsa Rating and News
GoFinsa provides a guide to Jamjoom Pharma, listed under ticker 4015, including its economic sector and factors to consider when studying the stock.
About Jamjoom Pharma and its business
Jamjoom Pharma (ticker 4015) operates in the Saudi market, manufacturing or distributing pharmaceutical products. The company description lists healthcare, pharmaceutical products, dermatological treatments and ophthalmic preparations among its areas of activity. Gas is also listed among other areas or products. This overview describes the stated business areas and products; it does not mean that each activity contributes equally to revenue or has produced any particular financial results. Source: https://stockanalysis.com/quote/tadawul/4015/company/
Information about Jamjoom Pharma stock
Jamjoom Pharma shares trade on the Saudi Exchange under ticker 4015. The company belongs to the pharmaceuticals sector. Following official disclosures and financial results can help readers understand the company’s position and the development of its business.
Jamjoom Pharma’s activities and company information
The company is classified in the pharmaceuticals sector in the Saudi market. Annual reports and official disclosures can be used to learn about its activities, revenue sources and operational developments.
The pharmaceuticals sector in the Saudi economy
The performance of listed companies in the pharmaceuticals sector may be affected by demand for their products and services, operating costs, competition, and economic and regulatory conditions. Companies differ in how sensitive they are to these factors, depending on their business models.
How to read the stock’s financial results
It is important to compare revenue, profit, cash flows and debt across several financial periods, and to understand the reasons for changes rather than relying on the results of a single quarter. Official announcements should also be reviewed for material events.
Factors that may affect the stock’s movement
Jamjoom Pharma’s share price may be affected by company results and disclosures, trends in the Saudi market, interest rates and investor expectations. A change in the share price alone does not indicate improved operating performance.
Investment risks
Potential risks include share-price volatility, changes in costs, weaker demand, competition and regulatory changes. Actual risks vary according to the company’s activities and financial position.
The stock’s investment strength according to the GoFinsa Saudi Stocks Index
The recorded rating for the stock in the GoFinsa GFSI is 84%. This is an independent analytical rating, not a guarantee of profit or a personal recommendation to buy.
Investing in Saudi stocks
The Saudi Exchange includes companies operating across a range of economic sectors. Investors can benefit from reviewing disclosures, comparing financial valuations, diversifying risk and setting an investment horizon before making a decision.
Following company news
The latest disclosures and news relating to Jamjoom Pharma stock can be followed through the news sources and official data available on GoFinsa. Readers should note the date of each item and how directly it relates to the company.
Jamjoom Pharma’s reference price
The recorded reference price is 128.0 SAR, dated 2026-10-08. This is a historical price, not a live quote or a confirmed current trading price.
Jamjoom Pharma’s rating in the GoFinsa GFSI
The rating assigned to the stock by the GoFinsa GFSI is 84%. This is a GoFinsa research rating, not a recommendation to buy or sell.
Overview of the pharmaceuticals sector
Jamjoom Pharma stock belongs to the pharmaceuticals sector on the Saudi Exchange. Companies in this sector may be affected by demand, competition, costs, and economic and regulatory conditions. Their risk profiles and revenue sources differ.
Trading through XTB and related risks
What does Jamjoom Pharma do?
Jamjoom Pharma (4015) belongs to the pharmaceuticals sector. The company’s potential business scope for research purposes includes manufacturing or marketing medicines and healthcare products. Specific details and subsidiary activities should be checked against the company’s latest official profile before publication.
Where does Jamjoom Pharma’s revenue come from?
When analyzing Jamjoom Pharma’s business model, the following potential sources of income should be reviewed against the company’s financial statements: sales of pharmaceutical products, distribution channels and exports, if any. Listing these items does not mean that each one is an actual contributor to the company’s revenue.
Factors that may affect Jamjoom Pharma’s performance
Relevant indicators to monitor in connection with Jamjoom Pharma’s business include pharmaceutical registrations, pricing, production costs and competition. Trends should be compared across multiple periods of the company’s actual results; growth or profitability should not be inferred without documented figures.
What to check in the annual disclosure
When studying Jamjoom Pharma (4015), first identify the date of the latest annual report, then review the description of actual activities, operating segments and revenue recognition policy. Read the notes to the financial statements rather than relying solely on management’s summary; the notes may reveal obligations or events that are not apparent in the headline figures. Confirm the identity of the listed entity, its subsidiaries and the nature of their operations before attributing any activity or project to the company. A trend in the pharmaceuticals sector should not be treated as evidence of revenue growth at this company unless supported by its published results.
How to distinguish genuine growth from accounting changes
To analyze Jamjoom Pharma, compare results for several equivalent periods and pay attention to non-recurring items, reclassifications and changes in the scope of consolidation. Higher revenue does not necessarily mean improved profitability if the cost of sales or expenses have risen more quickly. Examine operating and net profit margins, then consult management’s notes for explanations of changes. If reliable, up-to-date financial statements are unavailable, these remain analytical steps rather than a description of Jamjoom Pharma’s actual performance.
Cash flows and the ability to fund operations
When reviewing Jamjoom Pharma’s data, it is useful to distinguish accounting profit from cash generated by operations. Examine net operating cash flows, changes in working capital, capital expenditure and financing costs. A company may report profits while cash declines because of increases in receivables or inventory, or project-related payments. Conversely, cash flows may be temporarily affected by the timing of collections and payments. The company’s liquidity or solvency cannot be assessed without the relevant financial statements and notes.
Debt and financing costs: questions to consider
If Jamjoom Pharma has financing obligations, begin by identifying their maturities, the split between short- and long-term debt, borrowing costs and any contractual covenants. Test how changes in interest rates could affect earnings and cash flows, taking into account whether financing instruments carry fixed or variable rates. The importance of these questions varies with the company’s business model in the pharmaceuticals sector. This guide does not assume that the company has any particular level of debt or risk.
Comparing the stock with sector peers without misleading conclusions
For a fair comparison of Jamjoom Pharma stock, select companies with similar activities, revenue mixes, size and regulatory environments. Compare revenue growth, margins, return on capital and cash flows, then review differences in accounting and leverage. A lower price-to-earnings multiple than that of another company is not, by itself, enough to conclude that the stock is cheaper; the difference may reflect growth expectations, risk or earnings quality. If a company has losses or non-recurring profits, some valuation multiples may not be suitable for comparison.
How to interpret the reference price and its date
The reference price shown in this guide is historical and dated; it is not a live bid or offer. When assessing Jamjoom Pharma, check which trading session the price relates to and whether there have been capital changes, a share split or distributions that could affect historical comparisons. Do not confuse the previous closing price with the latest trade or the session’s average price. If market data is delayed, its date should be clearly shown, and a dated figure should not be used to infer a new daily trend.
Developing scenarios instead of predicting a specific price
Three scenarios can be used to study Jamjoom Pharma: improved business conditions, continuation of current conditions, and weaker demand or margins. For each scenario, define measurable assumptions such as sales volume, input costs or financing expenses, then compare the results with published financial statements when available. Do not set a price target without a valuation model and documented inputs, and do not present the positive scenario as the expected outcome. The aim is to understand how the investment may respond to new information.
Checklist before making an investment decision
Before investing in Jamjoom Pharma stock, confirm the ticker 4015, the company’s identity and the price date, then review the latest material disclosure, financial results and auditor’s notes, if any. Distinguish GoFinsa’s research rating from whether the investment suits your personal circumstances. Define your investment horizon and tolerance for loss, and consider your portfolio’s exposure to the pharmaceuticals sector. Review broker fees and the nature of the financial instrument: owning shares directly differs from trading derivatives or contracts for difference, which may involve additional risks.
أسئلة شائعة عن الشركة
What is Jamjoom Pharma’s stock ticker?
The stock trades on the Saudi Exchange under ticker 4015.
Which sector does Jamjoom Pharma stock belong to?
The stock belongs to the pharmaceuticals sector.
Is the GoFinsa rating a buy recommendation?
No. The rating is an analytical tool and is neither a personal investment recommendation nor a guarantee of future performance.